Benzinga · Apr 2, 2026
IP
NASDAQ · IPSC
Century Therapeutics, Inc.
Healthcare · Biotechnology
$1.94
Down-$0.09 (-4.43%)
Updated Sep 11, 2026, 3:51 AM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 50.91M
- P/E ratio
- -2.19
- Dividend yield
- 0.00%
- 52-week range
- $0.44 – $3.04
- Volume
- 510.03K
- Avg. volume
- 989.38K
Price performance
IPSC price history
1M range · 20 trading sessions · Daily adjusted prices
IPSC closed at $1.94 after 20 trading sessions, up 0.52% for the selected period.
- Last close
- $1.94
- Period change
- +0.52%
- Period low
- $1.92
- Period high
- $2.23
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $2.03 | $2.03 | $1.91 | $1.94 | 510.03K |
| Sep 9, 2026 | $2.07 | $2.10 | $2.03 | $2.03 | 293.08K |
| Sep 8, 2026 | $2.10 | $2.13 | $2.03 | $2.07 | 228.15K |
| Sep 4, 2026 | $2.06 | $2.15 | $2.06 | $2.11 | 300.38K |
| Sep 3, 2026 | $2.13 | $2.13 | $2.05 | $2.09 | 349.61K |
| Sep 2, 2026 | $2.03 | $2.135 | $2.03 | $2.11 | 465.9K |
| Sep 1, 2026 | $2.00 | $2.04 | $1.98 | $2.03 | 320.47K |
| Aug 31, 2026 | $2.00 | $2.06 | $1.97 | $2.05 | 374.21K |
| Aug 28, 2026 | $2.23 | $2.25 | $1.99 | $2.025 | 630.55K |
| Aug 27, 2026 | $2.15 | $2.25 | $2.15 | $2.23 | 525.71K |
| Aug 26, 2026 | $2.17 | $2.17 | $2.10 | $2.14 | 313.57K |
| Aug 25, 2026 | $2.13 | $2.205 | $2.12 | $2.17 | 542.82K |
| Aug 24, 2026 | $2.08 | $2.145 | $2.03 | $2.12 | 360.77K |
| Aug 21, 2026 | $2.05 | $2.085 | $2.02 | $2.07 | 330.59K |
| Aug 20, 2026 | $2.07 | $2.09 | $2.019 | $2.02 | 314.08K |
| Aug 19, 2026 | $1.99 | $2.115 | $1.99 | $2.11 | 448.68K |
| Aug 18, 2026 | $1.94 | $1.98 | $1.90 | $1.96 | 389.16K |
| Aug 17, 2026 | $1.92 | $1.95 | $1.89 | $1.95 | 414.88K |
| Aug 14, 2026 | $1.95 | $1.96 | $1.89 | $1.92 | 489.97K |
| Aug 13, 2026 | $1.98 | $2.025 | $1.91 | $1.93 | 546.55K |
Latest IPSC news
The latest Smart Investors Daily articles mentioning IPSC.
Stock researchCompany · Overview
IPSC research
Overview
Company profile and research snapshot.
Company profile
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $15.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 27, 2026 | Mizuho | Outperform | — |
| Apr 21, 2026 | HC Wainwright & Co. | Buy | — |
| Jan 20, 2026 | Piper Sandler | Overweight | — |
| Nov 17, 2025 | Leerink Partners | Market Perform | — |
| May 16, 2025 | Chardan Capital | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Feb 17, 2026
Reported Monday, iPSC-Derived NK Cells Clinical Trial Pipeline Gains Momentum With 12+ Active Companies Developing Off-The-Shelf Cancer Immunotherapy Treatments Across Multiple Indications
SeekingAlpha · Feb 9, 2026
Century Therapeutics: A Very Promising Contender In The Type I Diabetes Mellitus Functional Cure Race
Century Therapeutics (IPSC) aims at a durable âonce-and-doneâ Type 1 diabetes cure with hypoimmune iPSC beta cells; runway to 2029âclick here to read now.
Benzinga · Feb 5, 2026
Century Therapeutics Files Prospectus For Offering 176.087M Common Shares
SEC
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
